 We propose to evaluate the efficacy and time to viral suppression with DTG3TCABC FDC as initial therapy for AHI acute HIV infection, as well as the feasibility of prompt administration using a rapid HLA-B57 human leukocyte antigen screening antibody assay. In addition to validating the restriction of RCI resting cell infection by ART antiretroviral therapy including a DTG-based regimen initiated during AHI, we will seek correlations between low RCI, residual GALT gastrointestinal associated lymphoid tissue HIV expression, and measures of immune activation. We hypothesize that rapid reduction in plasma viremia with this regimen will limit the area under the pre-ART viral load curve, and thus reduce the latent reservoir size as measured by a viral outgrowth assay one to two years following ART start, and as compared with the latent reservoir size in acutely infected individuals started on regimens without an integrase inhibitor based regimen. In addition, we will examine the longitudinal impact of the proposed integrase-based regimen initiated during the acute period on immune activation through week 96. If residual viral expression and persistent immune dysfunction is related to the burden of the latent viral reservoir and presumably its periodic activation these abnormalities should be ameliorated by early ART with rapid viral suppression. Finally, we will evaluate dolutegravir levels in plasma and GALT and whether rapid viral suppression with the proposed dolutegravir-based ART regimen impacts HIV RNA levels in GALT. 